FRACTALKINE-ANTAGONISTS: A new treatment for inflammation and cardiac protection

Kancera is developing KAND567 against  cardiovascular diseases

Great medical need but lack of innovation, until now.

The problem:
Inflammation causes half of the tissue damage in a heart attack 

The solution:
KAND567 can slow down the acute inflammation

This is how KAND567 works

Next step
Clinical evaluation in patients 

The future
From acute to chronic, from cardiovascular disease to cancer